Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver‐Targeting Acetyl‐CoA Carboxylase Inhibitor (PF‐05221304): A Three‐Part Randomized Phase 1 Study

por Bergman, Arthur, Carvajal‐Gonzalez, Santos, Tarabar, Sanela, Saxena, Aditi R., Esler, William P., Amin, Neeta B.
Publicado 2020

Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

por Fediuk, Daryl J., Nucci, Gianluca, Dawra, Vikas Kumar, Cutler, David L., Amin, Neeta B., Terra, Steven G., Boyd, Rebecca A., Krishna, Rajesh, Sahasrabudhe, Vaishali
Publicado 2020

Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): ratio...

por Amin, Neeta B, Darekar, Amanda, Anstee, Quentin M, Wong, Vincent Wai-Sun, Tacke, Frank, Vourvahis, Manoli, Lee, Douglas S, Charlton, Michael, Alkhouri, Naim, Nakajima, Atsushi, Yunis, Carla
Publicado 2022